Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter Kraft, Ph.D.

Co-Author

This page shows the publications co-authored by Peter Kraft and Graham Colditz.
Connection Strength

0.834
  1. Simplified Breast Risk Tool Integrating Questionnaire Risk Factors, Mammographic Density, and Polygenic Risk Score: Development and Validation. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):600-607.
    View in: PubMed
    Score: 0.235
  2. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):282-8.
    View in: PubMed
    Score: 0.103
  3. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res. 2007; 9(1):R18.
    View in: PubMed
    Score: 0.090
  4. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case-control study. PLoS Med. 2018 09; 15(9):e1002644.
    View in: PubMed
    Score: 0.050
  5. Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. J Clin Oncol. 2014 Oct 01; 32(28):3111-7.
    View in: PubMed
    Score: 0.038
  6. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
    View in: PubMed
    Score: 0.038
  7. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013 Apr; 45(4):385-91, 391e1-2.
    View in: PubMed
    Score: 0.035
  8. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 2009 May; 41(5):579-84.
    View in: PubMed
    Score: 0.026
  9. Breast cancer susceptibility loci and mammographic density. Breast Cancer Res. 2008; 10(4):R66.
    View in: PubMed
    Score: 0.025
  10. Haplotypes of the estrogen receptor beta gene and breast cancer risk. Int J Cancer. 2008 Jan 15; 122(2):387-92.
    View in: PubMed
    Score: 0.024
  11. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007 Jul; 39(7):870-4.
    View in: PubMed
    Score: 0.023
  12. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res. 2007 Apr 01; 67(7):2951-6.
    View in: PubMed
    Score: 0.023
  13. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer. 2006 Oct 15; 119(8):1976-84.
    View in: PubMed
    Score: 0.022
  14. Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 2006 Feb 15; 66(4):2468-75.
    View in: PubMed
    Score: 0.021
  15. A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Breast Cancer Res. 2006; 8(5):R54.
    View in: PubMed
    Score: 0.021
  16. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005 12; 5(12):977-85.
    View in: PubMed
    Score: 0.021
  17. CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer. 2005 Aug 20; 116(2):267-74.
    View in: PubMed
    Score: 0.020
  18. Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study. Breast Cancer Res. 2004; 6(4):R416-22.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.